FAAN

Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management

Retrieved on: 
Wednesday, September 6, 2023
Science, Neurology, Radiology, Biotechnology, Research, Health, Clinical Trials, Other Health, Octave, Depression, Anxiety, Neurodegenerative disease, Oklahoma Medical Research Foundation, BIIB, Multiple sclerosis, Doctor of Philosophy, MS, Organization, MRI, Neuroscience, Rocky Mountains, MD, Patient, Practitioner, OMRF, Orlando Health, FAAN, Medical imaging, Nursing, Biogen

The study will utilize the Octave® Precision Care Solution (Octave®Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center.

Key Points: 
  • The study will utilize the Octave® Precision Care Solution (Octave®Solution) to evaluate 150 patients with MS at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center.
  • Octave’s Solution provides neurologists and their patients with quantitative, objective metrics to facilitate informed care and shared decision making to provide a more personalized MS care approach.
  • The study is expected to be conducted for 12 months following patient enrollment.
  • “For those of us who have been researching and treating MS for decades, it is a promising step forward for us and, most importantly, for our patients.”

Confluent Health Announces Finalists for Annual Team Leader of the Year Award

Retrieved on: 
Wednesday, September 6, 2023
Sport, Texas League Pitcher of the Year Award, Team leader, Criterion, DNP, Name, Patient, Environment, Team, Conference, FAAN, Management, Nursing

LOUISVILLE, Ky., Sept. 6, 2023 /PRNewswire-PRWeb/ -- Confluent Health, a leading healthcare organization dedicated to the transformation of healthcare, is proud to announce the five finalists for the esteemed Team Leader of the Year Award.

Key Points: 
  • The winner of the Team Leader of the Year Award will be announced on the evening of Saturday, September 23rd during the organization's annual Team Leaders Conference taking place in Austin, Texas.
  • What is the Team Leader of the Year Awards: Confluent Health's Team Leader of the Year Award is our most prestigious award given annually at the Team Leaders Conference.
  • What are the Criteria for the Team Leader of the Year Awards: Nominees of the Team Leader of the Year Award are submitted by Confluent Health partner company leadership, with each partner company allowed to nominate one candidate.
  • What is the Team Leader Conference: Confluent Health's Team Leaders Conference is a celebration of our clinical visionaries, change-makers and leaders who demonstrate remarkable leadership and dedication.

Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma

Retrieved on: 
Wednesday, September 6, 2023
Radiation, University, Temozolomide, Neuro-Oncology (journal), PALO, Eflornithine, Cancer, Pharmacokinetics, Toxicity, Doctor of Philosophy, PFS, Glioblastoma, ORR, Huntsman Cancer Institute, MD, Patient, Jon, Entrepreneurship, Lomustine, Neuro, Therapy, FAAN, Glioma, Safety, Pharmaceutical industry, Medical imaging

PALO ALTO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced today that the first patient has been enrolled in its Phase 1b study combining temozolomide and eflornithine in patients newly diagnosed with glioblastoma.

Key Points: 
  • PALO ALTO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases, announced today that the first patient has been enrolled in its Phase 1b study combining temozolomide and eflornithine in patients newly diagnosed with glioblastoma.
  • Orbus Therapeutics is currently conducting a Phase 3 clinical trial, referred to as the STELLAR study, to evaluate its eflornithine oral solution in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant temozolomide chemotherapy.
  • The initiation of this Phase 1b study is part of Orbus’ ongoing efforts to develop a new treatment option for patients with malignant glioma.
  • Temozolomide is the current standard of care in patients with newly diagnosed glioblastoma.”
    The Phase 1b study is an open-label, single arm, dose-limiting toxicity clinical trial that will include approximately 8 leading neuro-oncology clinical trial centers in the United States.

Philips, Emory School of Nursing and Partners Team up to Support Farm Worker Family Health Program and Clinic

Retrieved on: 
Tuesday, September 5, 2023
Nursing, Education, Health, Agriculture, Natural Resources, General Health, University, Blood pressure, Emory University, Emory School, Health Resources and Services Administration, AED (non-profit), Partnership, Health equity, Nurse education, School, Student, Brooks, H-2A, Work, Georgia Department of Public Health, Hearing, AEX, Faculty, RN, PHG, Nell Hodgson Woodruff School of Nursing, FAAN, BMI, Ellenton, MPH, NYSE, Community health, Doctor of Philosophy

Due to the nature of their work, access to and continuity of health care is a major challenge.

Key Points: 
  • Due to the nature of their work, access to and continuity of health care is a major challenge.
  • The program provides access to care for farmworkers and families in Colquitt, Tift, Brooks and Cook counties.
  • It also offers a faculty-led educational training and service-learning opportunity for Emory University undergraduate and graduate nursing students, in partnership with students from other health profession education programs across Georgia.
  • The Farm Worker Family Health Program, now in its 30th year, is organized by the Emory School of Nursing and held in partnership with the Georgia Ellenton Farmworker Health Clinic in Colquitt County and a host of state, local and educational partners.

Find Therapeutics Appoints Robert L. Glanzman, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, September 5, 2023
Duke University, University, Wake Forest University, FTX, Biotechnology, Roche, American Academy, Medicine, CMO, Multiple sclerosis, MS, Novartis, Patient, Michigan State University, Neurology, Therapy, American Academy of Neurology, FAAN, Pfizer, Pharmaceutical industry

MONTREAL, Sept. 5, 2023 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Robert L. Glanzman, M.D.

Key Points: 
  • MONTREAL, Sept. 5, 2023 /PRNewswire/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the appointment of Robert L. Glanzman, M.D.
  • FAAN, as Chief Medical Officer.
  • Dr. Glanzman is a board-certified neurologist and Fellow of the American Academy of Neurology with over 20 years of experience in neuroscience-related clinical development.
  • Prior to joining industry, Dr. Glanzman held an appointment as Associate Clinical Professor of Neurology at Michigan State University.

Dr. Eileen K. Fry-Bowers, Dean of the USF School of Nursing & Health Professions, Launches First Nurse Health Equity Scholars Program with Alameda Health System

Retrieved on: 
Thursday, August 31, 2023
Partnership, University, Highland Hospital, MSN, USF, AHS, Health equity, MBA, Doctor of Philosophy, BSN, DNP, CPNP, Student, Social justice, SAN, JD, School, Alameda Health System, RN, Health, FAAN, Skin, Safety, Nursing, Science, San Francisco Bay Area, Teaching

SAN FRANCISCO, Aug. 31, 2023 /PRNewswire-PRWeb/ -- Eileen K. Fry-Bowers, PhD, JD, RN, CPNP, FAAN, dean of the University of San Francisco (USF) School of Nursing and Health Professions, has launched the first Nurse Health Equity Scholars program in an academic partnership with clinical safety net partner Alameda Health System (AHS). The Nurse Health Equity Scholars Program is a unique and evidence-based approach to providing longitudinal clinical learning experiences in the public health sector - the first of its kind in California.

Key Points: 
  • The Nurse Health Equity Scholars Program is a unique and evidence-based approach to providing longitudinal clinical learning experiences in the public health sector - the first of its kind in California.
  • As a member of the Nurse Health Equity Scholars program, I deeply desire to change health care."
  • "Alameda Health System is pleased to welcome USF's Nurse Health Equity Scholars," said Lofton.
  • We are excited to launch the Nurse Health Equity Scholars program and promote health equity and justice."

HPRC Physical Therapy Announces Partnership with Excel Physical Therapy

Retrieved on: 
Thursday, August 31, 2023
MPT, CSCS, Partnership, MTC, PTPN, LAT, Education, Marketing, CHT, HRPC, PT, MBA, DNP, Trust, Patient, Microsoft Excel, OTR/L, Ecosystem, Health, FAAN, Health care, Online shopping, Nursing, Motion

COLUMBUS, Ga., Aug. 31, 2023 /PRNewswire-PRWeb/ -- HPRC Physical Therapy (HPRC) proudly announces its latest partnership with Excel Physical Therapy (Excel PT), a therapist-owned physical therapy practice located in Hampton, GA. This partnership is an exciting opportunity for both companies to expand their reach and provide even more comprehensive care to patients throughout the region.

Key Points: 
  • COLUMBUS, Ga., Aug. 31, 2023 /PRNewswire-PRWeb/ -- HPRC Physical Therapy (HPRC) proudly announces its latest partnership with Excel Physical Therapy (Excel PT) , a therapist-owned physical therapy practice located in Hampton, GA.
  • "We couldn't be more excited to be joining the HPRC Physical Therapy family.
  • This partnership expands access to our physical therapy services to 15 clinics across Alabama, Georgia, and South Carolina.
  • To schedule an appointment with one of Excel PT's expert therapists, visit their website at excelptotga.com or call 770-603-7050.

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Retrieved on: 
Monday, August 28, 2023
Huntington's disease, Pit additive, KINECT, Lancet Neurology, Week, Disease, McGovern Medical School, Neurocrine Biosciences, Clinical Global Impression, Movement disorder, The Lancet, MDS, Capsule, Movement, TMC, SAN, Chorea, Parkinson's disease, FANA, Neurology, Poster, FAAN, FDA, Safety, Pharmaceutical industry, HD

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD), including exploratory results from the Phase 3 KINECT®-HD study, which showed consistently greater improvements in HD chorea with INGREZZA versus placebo from Week 2 to Week 12. These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.

Key Points: 
  • These data will be presented at the MDS International Congress of Parkinson's Disease and Movement Disorders®August 27-31 in Copenhagen, Denmark.
  • "The exploratory analysis from our KINECT-HD study further exemplifies the value of INGREZZA as a now approved medication for HD chorea with improvements seen with treatment as early as two weeks," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences.
  • "This exploratory analysis has increased our insight regarding the early and sustained improvements in chorea severity."
  • Additional HD chorea presentations at the MDS International Congress of Parkinson's Disease and Movement Disorders include:

NCSBN Elects National Leadership and Considers New Business with its Members at its 2023 Annual Meeting

Retrieved on: 
Thursday, August 24, 2023
FRE, College, Education, Minnesota Advanced Practice Registered Nursing, MSM, Compact, History, Virginia Board of Health, Doctor of Philosophy, APRN, DA, CSAC, Nova Scotia College of Early Childhood Education, Registered nurse, CNE, Annual general meeting, NCSBN, Education minister, Artificial intelligence, RN, FAAN, Management, Nursing

Chicago, Aug. 24, 2023 (GLOBE NEWSWIRE) -- NCSBN met in Chicago Aug. 16-18, 2023, to consider pertinent association business with its members.

Key Points: 
  • Chicago, Aug. 24, 2023 (GLOBE NEWSWIRE) -- NCSBN met in Chicago Aug. 16-18, 2023, to consider pertinent association business with its members.
  • NCSBN Board of Directors President Jay Douglas, MSM, RN, CSAC, FRE, executive director, Virginia Board of Nursing, noted, “In 2023 NCSBN celebrated its 45th Anniversary.
  • Approved the use of remote testing and artificial intelligence (AI) security technology by NCSBN Exams.
  • “These DA actions will enhance public protection nationally and internationally, preparing NCSBN for the future,” commented Douglas.

Top Rated Physical Therapy Group Secures Partnership with University of Louisville Athletics

Retrieved on: 
Wednesday, August 23, 2023
KFC Yum! Center, 1895 Louisville Athletic Club football team, University of Louisville School of Medicine, CSCS, Partnership, University, Confluence, Jim Patterson Stadium, PRPT, Therapy, Virginia Credit Union Stadium, PT, OCS, MBA, Research, History, MAPP, DNP, Athlete, Occupational therapy, Partner, Patient, Trustee, Sport, Radio, UofL, Dr. Mark & Cindy Lynn Stadium, DPT, Family, FAAN, SCS, Nursing

LOUISVILLE, Ky., Aug. 23, 2023 /PRNewswire-PRWeb/ -- Physical Therapy (PRPT) takes great pride in announcing its first-ever collaboration with the University of Louisville (UofL) and Cardinal Sports as an Official Partner of University of Louisville Athletics for the upcoming 2023-2024 athletic season.

Key Points: 
  • ProRehab Physical Therapy, one of Kentucky's top rated physical and occupation therapy experts, is now a Louisville Athletics sponsor
    LOUISVILLE, Ky., Aug. 23, 2023 /PRNewswire-PRWeb/ -- Physical Therapy (PRPT) takes great pride in announcing its first-ever collaboration with the University of Louisville (UofL) and Cardinal Sports as an Official Partner of University of Louisville Athletics for the upcoming 2023-2024 athletic season.
  • "This partnership aligns perfectly with our mission to positively impact the communities we serve by delivering best-in-class musculoskeletal care and advancing physical therapy practices through evidence-based research."
  • CEO of Confluent Health, Dr. Kristi Henderson, DNP, FAAN, also expressed her enthusiasm for the partnership, stating, "We are excited to see ProRehab Physical Therapy collaborate with University of Louisville Athletics.
  • "The partnership between ProRehab Physical Therapy and University of Louisville Athletics has created a power team between top-tier physical therapists and top-performing collegiate athletes," added Dr. Benz.